Key Takeaways:
(Bloomberg) -- Shares of Humana Inc. (NYSE: HUM) surged 48% over the past month, with the health insurer’s concentrated focus on Medicare Advantage helping it dramatically outperform peers after favorable government rate decisions and a strong first-quarter earnings report.
"Humana's surge reflects a stack of catalysts centered on Medicare Advantage," Bernstein noted in a recent report, raising its price target on the stock to $288. The firm cited improved final MA rates and positive first-quarter utilization signals as key drivers for the re-rating.
The stock’s 48% one-month gain, which brought its price to around $303, far outpaces the 19% rise in UnitedHealth Group (NYSE: UNH) and a modest 2.5% increase for Cigna Group (NYSE: CI) over the same timeframe. Humana reported first-quarter adjusted earnings of $10.31 per share on $39.65 billion in revenue, beating the consensus estimate of $10.20.
The rally marks a significant recovery for a stock that remains down 32% over the past five years, suggesting the recent move is more of a rebound than a new bull market. Investors are now watching if the company can maintain momentum, with the next major catalysts being the October Star Ratings release and continued execution on its full-year guidance of at least $9 in adjusted EPS.
Humana’s outperformance is directly tied to its business model, which is heavily concentrated in government-sponsored Medicare Advantage (MA) plans. This structure allows it to benefit disproportionately when regulatory news, such as the recent favorable MA rate decision, is positive. The company’s individual MA membership grew 22% year-to-date, reinforcing the strength in its core market.
In contrast, UnitedHealth Group’s business is more diversified. While it also posted a strong quarter and raised its full-year EPS guidance to above $18.25, its mix of commercial plans and the large Optum health services segment dilutes the direct impact of the MA tailwind. Cigna, the laggard of the group with a 4% year-to-date gain, is even less exposed to the MA cycle, with its business tilting toward commercial insurance and its Express Scripts pharmacy benefit manager.
While Humana has been the standout performer over the last month, the one-year view shows UnitedHealth leading the trio with a 33% gain, compared to 28% for Humana and a negative return for Cigna. The broader market was mixed Tuesday, with defensive health insurance stocks like Humana (+7%) and UnitedHealth (+3%) bucking a technology-led downturn as the 10-year Treasury yield climbed 5 basis points to 4.46%.
This article is for informational purposes only and does not constitute investment advice.
